Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
GROWTH
KisqaliⓇ delivers strong growth across all geographies based on
increasing recognition of overall survival and quality of life benefits
Sales evolution
USD m, % cc
Ex-US
US
+33%
357
285
208
187
149
98
Q4 2021
Q4 2022
KISQALI
US MBC NBRx share1
R3M, %
12%
Mar 2022
27%
Nov 2022
FY sales USD 1.2bn (+38% cc)
NBRx share 27%1
NCCN update²: The only Category 1 treatment for
1L mBC with Al; Category 1 for 1L with fulvestrant
RIGHT Choice Ph2 study: KisqaliⓇ doubled median
PFS in patients with aggressive HR+/HER2- MBC
compared to CT3
NATALEE final analysis expected H2 2023
HARMONIA H2H (vs. Ibrance®) recruiting
Approved in China for pre/peri-menopausal
HR+/HER2- MBC
mBC metastatic breast cancer.
R3M-rolling 3 months. H2H - head-to-head. 1. Of CDK4/6 mBC market, US Nov'22 R3M. 2. NCCN Guidelines updated as of 27-Jan-2023. 3. RIGHT Choice evaluated Kisqali Ⓡ plus endocrine
therapy (ET) vs. combination chemotherapy (CT) in 1L pre- and perimenopausal patients with aggressive forms of HR+/HER2- mBC, including patients with visceral crisis. Data presented at SABCS: mPFS 24.0 vs. 12.3 months; HR=0.54;
p=.0007.
27 Investor Relations | Q4 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation